Fibronostics Completes Acquisition of Stone Clinical Laboratories

Fibronostics has finalized its acquisition of Stone Clinical Laboratories, LLC, enhancing its position in the U.S. laboratory market. This move aims to accelerate the development of non-invasive diagnostics for metabolic and liver diseases, particularly focusing on metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD).

The acquisition, announced on October 27, 2025, allows Fibronostics to strengthen its research and development capabilities. This initiative aligns with recent industry milestones, including the approvals of Madrigal Pharmaceuticals‘ RezdiffraTM and Novo Nordisk‘s Wegovy®, alongside Roche‘s acquisition of 89Bio. These developments indicate a rising investment in MASH and MASLD therapeutics, underscoring the need for reliable diagnostics that can identify patients earlier and monitor disease progression effectively.

Brock Smith, Chief Executive Officer of Fibronostics, emphasized the importance of this acquisition, stating, “With the acquisition of Stone Clinical Laboratories, Fibronostics expands its U.S. laboratory infrastructure and operational expertise. This strengthens our ability to accelerate innovation in non-invasive diagnostics and enhance collaborations with pharmaceutical and healthcare partners addressing the global burden of MASH and MASLD.”

The integration of Stone Clinical Laboratories will bolster Fibronostics’ proprietary digital health platforms, including LIVERFASt®. These combined resources are expected to enhance biomarker development and support clinical validation studies, which are critical for therapeutic innovation and patient management.

“Therapeutic breakthroughs in MASH and MASLD are reshaping liver care,” Smith added. “As treatment options expand, the need for precise and accessible diagnostics becomes more critical. This acquisition positions Fibronostics to lead in providing scalable solutions that bridge diagnostics and therapeutics.”

This acquisition marks a significant advancement in Fibronostics’ growth strategy. The newly combined organization is well-prepared to collaborate with biopharma innovators, healthcare systems, and payers to facilitate early detection and improve outcomes for patients globally.

Fibronostics is recognized as a global health technology company dedicated to non-invasive diagnostic solutions for chronic diseases, particularly those affecting the liver and metabolic systems. Its flagship platform, LIVERFASt®, offers clinicians a rapid and accurate assessment of liver health, contributing to better patient outcomes. The company actively partners with pharmaceutical firms, diagnostic laboratories, and healthcare systems worldwide to advance next-generation liver diagnostics.

For further inquiries, please contact:

Brock Smith, CEO
Fibronostics US Inc.
Phone: 1-888-552-1603
Email: [email protected]